Ansiten 5

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ansiten 5

Quick Facts

Property Description
Active ingredient Buspirone hydrochloride
Form Oral tablet
Pharmacological class Anxiolytic (Azapirone class)
Common use Management of Generalized Anxiety Disorder (GAD)
Origin Synthetic (man-made)

What is Ansiten 5 (Buspirone Overview)?

Ansiten 5 is a prescription-only anxiolytic (anti-anxiety) medication used to help manage and relieve the chronic symptoms of anxiety. Its single active ingredient is Buspirone hydrochloride, typically provided as a 5 mg strength oral tablet. The drug is classified as an Azapirone and is chemically distinct from other anxiety treatments. Buspirone is recognized as an anxiolytic used for the treatment of generalized anxiety disorder.

Form, Composition, and Differentiation

Ansiten 5 is manufactured as a single-ingredient oral tablet. The compound is synthetic, ensuring a consistent chemical structure. The tablets contain the active 5 mg ingredient plus various inactive substances, such as lactose, which are necessary to form the pill's physical structure and aid in the controlled delivery of the medication.

Ansiten 5’s primary differentiator lies in its mode of action, which involves modulating the serotonin system in the brain. Buspirone has a unique mechanism of action and lacks the strong sedative properties or significant risk of dependence associated with benzodiazepines. This profile makes it an option for long-term anxiety management where minimizing sedation and dependence potential is a primary goal.

Regulatory References

  1. NIH: Buspirone (StatPearls)
  2. NIH: Buspirone review

What side effects are possible with Ansiten 5?

Possible Side Effects and Safety Information

The safety profile of Ansiten 5 (buspirone hydrochloride) is structured by government regulatory bodies based on the frequency and type of documented adverse reactions in clinical trials and post-marketing reports.

Frequency-Classified Adverse Reactions

Adverse reactions are classified into System-Organ-Classes (SOCs) and assigned a frequency rating based on regulatory standards. Some of the most frequently documented effects include:

Classification Examples of Adverse Reactions (SOC)
Very Common (≥ 1/10) Dizziness, Headache, Somnolence (Nervous System)
Common (≥ 1/100 to < 1/10) Nausea, Dry mouth (Gastrointestinal); Insomnia, Nervousness (Psychiatric); Fatigue (General)
Uncommon (≥ 1/1,000 to < 1/100) Suicidal ideation (Psychiatric); Hypotension, Hypertension (Vascular)

Serious Adverse Reactions and Safety Restrictions

Official labeling documents specific serious reactions and safety constraints. Serotonin Syndrome and Extrapyramidal Disorders (such as akathisia, dyskinesia, and dystonia) have been documented in post-marketing reports, typically categorized as rare or very rare.

Safety Constraints and Special Populations:

  • Contraindications: Use is contraindicated with a Monoamine Oxidase Inhibitor (MAOI).
  • Hepatic/Renal Impairment: Use is not recommended in individuals with severe hepatic impairment or severe renal impairment (creatinine clearance < 20 mL/min/1.72 m^2).
  • Time-Related Pattern: A syndrome of restlessness has been reported to appear shortly after treatment initiation in a small fraction of patients.
  • Prior Treatment: Buspirone does not prevent withdrawal symptoms from central nervous system depressants; prior therapy requires gradual withdrawal.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented information regarding overdose with Ansiten 5 (Buspirone), based on authoritative governmental regulatory documents.

Documented Overdose Manifestations

Symptoms and signs of overdose reported in regulatory sources typically affect the central nervous system and gastrointestinal tract. These may include:

  • Severe drowsiness or dizziness
  • Nausea and vomiting
  • Pinpoint pupils (miosis)
  • Gastric distress or upset stomach
  • Loss of consciousness (associated with severe intoxication)

In cases of overdosage involving this drug alone, recovery has typically been complete. However, all fatal outcomes reported in the context of overdosage have involved the ingestion of multiple drugs and/or alcohol.

Required Emergency Action

Immediate medical help must be sought at once if an overdose is suspected or if any of the above serious symptoms occur. Do not wait for symptoms to worsen.

Overdose Management and Considerations

Treatment for overdose is generally symptomatic and supportive, as there is no specific antidote listed in the regulatory documents. Monitoring of vital signs such as respiration, pulse, and blood pressure is required.

Special consideration should be given to individuals with pre-existing severe hepatic (liver) or renal (kidney) impairment, as official labeling indicates that these conditions can lead to significantly elevated drug levels and an increased risk of adverse effects.

Therapeutic Uses of Ansiten 5

Ansiten 5 is commonly used to help with conditions characterized by periods of heightened symptoms such as Generalized Anxiety Disorder (GAD), where it provides support that helps ease the overall symptom burden of excessive worry. This application is relevant for easing symptoms that interfere with daily functioning and is applied in addressing symptom clusters that may become intense or disruptive.

The medication is relevant in contexts marked by increased discomfort or tension and is used for conditions presenting with systemic or localized discomfort. This profile is often relevant when supportive symptom management is appropriate and when functional stability is affected. The medication is applied in addressing symptom clusters that create noticeable physiological strain, such as symptoms related to heightened physiological activity and symptoms that interfere with daily functioning. Symptomatic relief contributes to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability.


Quick Fact: Support for Chronic Worry
Primary Domain Generalized Anxiety Disorder (GAD)
Target Symptoms Symptoms related to heightened physiological activity
Key Benefit Supports general well-being, assists with maintaining functional stability
Usage Context Applied in scenarios where additional management of discomfort is required

Eligibility and Restrictions for Use

Ansiten 5 (Buspirone hydrochloride) is officially designated for use in adult patients with Generalized Anxiety Disorder (GAD). The eligibility profile is strictly defined by regulatory bodies, outlining which populations are approved, restricted, or prohibited from using the medication.


Who Cannot Use (Contraindications)

  • Hypersensitivity: Individuals with a known allergy to buspirone or any of the tablet's ingredients must not use the medicine.
  • MAOIs: Use is contraindicated if a patient is currently taking a Monoamine Oxidase Inhibitor (MAOI) or has discontinued one within the preceding 14 days.
  • Severe Organ Impairment: Administration to patients with severe hepatic (liver) impairment or severe renal (kidney) impairment is not recommended due to increased drug levels and a prolonged half-life.

Conditional and Restricted Use

  • Pediatric Use: The medication is not recommended for children and adolescents under 18 years of age, as the safety and effectiveness in this population are not established by regulatory data.
  • Mild to Moderate Organ Impairment: Patients with non-severe renal or hepatic impairment may be eligible, but use requires caution and often necessitates a reduced starting dose.
  • Pregnancy and Lactation: While some authorities classify the drug as a lower risk (Category B), other international regulatory bodies formally state that Ansiten 5 is contraindicated during both pregnancy and breastfeeding. The decision to use it requires careful consideration of the risks versus the benefits.

What should I know about interactions with other medicines?

Ansiten 5 Interactions with other medicines and products

Formally Contraindicated Combinations

Co-administration of Ansiten 5 with Monoamine Oxidase Inhibitors (MAOIs), including reversible MAOIs such as Linezolid or Intravenous Methylene Blue, is contraindicated. This restriction applies up to 14 days after stopping either Ansiten 5 or the MAOI. The drug is also contraindicated in conditions of severe hepatic insufficiency and severe renal impairment ( CrCl < 20, ml/min/1.72 m^2) due to impaired clearance resulting in increased systemic exposure.


Interactions Affecting Drug Exposure

Ansiten 5 is primarily metabolized via the Cytochrome P450 3A4 (CYP3A4) enzyme, which governs most pharmacokinetic interactions.

Interaction Type Interacting Substances (Examples) Regulatory Outcome
Inhibition (Increased exposure) Itraconazole, Erythromycin, Nefazodone, Ritonavir Increased plasma concentrations (e.g., Itraconazole increases AUC up to 19-fold)
Induction (Decreased exposure) Rifampin, Phenobarbital, Carbamazepine, Dexamethasone Reduced buspirone exposure and potentially diminished effect

Pharmacodynamic and Other Interactions

Co-administration with other serotonergic agents (e.g., SSRIs, Triptans, Tryptophan, St. John's Wort) is associated with a documented increased risk of serotonin syndrome. Use with alcohol and other Central Nervous System (CNS) depressants should be avoided due to the potential for enhanced effects. Consumption of large quantities of Grapefruit Juice is documented to increase buspirone plasma concentrations via CYP3A4 inhibition, and intake must be consistent relative to food to prevent variable absorption.

Mechanism of Action

The Mechanism of Action for Ansiten 5 (Buspirone)

Targeted Modulation of Central Serotonin Receptors

Ansiten 5's action is defined by its high-affinity interaction with the Serotonin 5-HT1A receptor in the central nervous system, where it acts as a partial agonist. This targeted engagement in the brain's limbic system is the core molecular step, leading to the gradual modulation of activity within this circuitry. The drug specifically avoids the GABAA receptor complex. The drug's CNS influence is exerted entirely through the modulation of monoamine systems, including weak antagonism at D2 dopamine receptors.


Time-Dependent Autoreceptor Cascade

The full effect is achieved through a time-dependent mechanistic cascade involving 5-HT1A autoreceptors, which initially inhibit serotonin release before becoming desensitized over a period of 2–4 weeks. This necessary adaptation process removes the initial inhibitory brake, resulting in a net increase in serotonergic outflow and sustained modulation of 5-HT1A receptor signaling. This reliance on a slow process dictates the delayed physiological onset and means the mechanism is physiologically constrained from producing immediate, rapid effects.

Dosage and Administration Information

Administration Guidelines

Ansiten 5 is formulated as an oral tablet and is available in strengths including 5 mg, 7.5 mg, 10 mg, 15 mg, and 30 mg. The tablets are typically scored to allow for accurate division, facilitating dose adjustments.


Dosing Protocol and Schedule

The medication is administered in divided daily doses to maintain consistent levels. The standard adult starting dose is 7.5 mg twice a day, totaling 15 mg daily. The dosage may be increased by 5 mg per day at intervals of 2 to 3 days until the desired response is achieved. The maximum recommended total daily dose is 60 mg. Since the onset of full therapeutic effect may take one to two weeks, the usefulness of the treatment should be periodically reassessed during long-term use.


Special Use Conditions

Instruction Detail
Intake Timing Must be taken consistently—either always with food or always without food—to ensure stable absorption.
Dietary Restriction Patients must avoid consuming grapefruit and grapefruit juice while taking the medication.
Missed Dose Rule If a dose is missed, skip it and return to the regular dosing schedule; do not take a double dose to make up for the skipped one.
Population Constraint The drug is not recommended for use in patients with severe hepatic (liver) or renal (kidney) impairment. Use has not been established for pediatric patients.

These parameters define the frequency, dosage limits, and consistency in intake conditions required for the use of the medication.

Recent Clinical Evidence

Evidence for use in Generalized Anxiety Disorder (GAD)

The research for Ansiten 5 (Buspirone) has focused mainly on its evaluation in conditions characterized by fluctuating or episodic manifestations, specifically Generalized Anxiety Disorder (GAD). The core research includes multiple short-term Randomized Controlled Trials (RCTs). These studies were structured to examine whether Ansiten 5, when compared with a placebo (an inactive pill), influenced outcomes in adult outpatients with GAD.

Research examined outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level, which are common concerns in GAD. Research examined changes in symptom intensity using standardized rating scales, and data show patterns related to symptom evolution in the observed populations. These initial studies form part of the broader evidence landscape for GAD.


Short-Term and Long-Term Follow-up Data

Studies exploring short-term symptom changes monitored responses over defined time intervals, typically lasting between three and eight weeks. The findings indicate that measured changes were generally observed after several weeks of study monitoring—often two to four weeks—in the studied populations.

Regarding extended use, the primary evidence that was reviewed for the indication involved follow-up durations that were limited. While some non-controlled studies monitored patients for up to one year, long-term effects are not fully established, and evidence is limited regarding the durability of these patterns over years.


Evidence in Special Populations

Ansiten 5 was evaluated in adult populations that included individuals with coexisting symptoms, such as those reporting mild depressive symptoms alongside their GAD. Studies describe that this group was observed in some of the core research trials.

Research has also explored the evaluation of Ansiten 5 in pediatric populations (children and adolescents), but the findings were mixed, and data for this specific age group are still emerging. Regarding older adults, data for certain groups remain insufficient, and results apply only to the populations studied.

Key Studies & References

  1. Label: BUSPIRONE HYDROCHLORIDE tablet (Official FDA Label/DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Ansiten 5 (FAQ)

Q: What is the main difference between Ansiten 5 and similar medications I've heard about?

Official product information indicates that this medication is chemically and pharmacologically distinct from benzodiazepines. Unlike those agents, it lacks the strong sedative properties and does not have anticonvulsant or muscle relaxant effects. This unique profile is one of the key differentiators described in regulatory documents.

Q: Does Ansiten 5 interact with over-the-counter supplements like vitamins?

According to the official label, no specific interactions are known to occur between this medicine and vitamins. However, the product information recommends always discussing all supplements, herbal products, and vitamins being used with a healthcare professional. This guidance helps maintain the stability of the medication’s effect and is a standard safety measure.

Q: Can older adults typically use Ansiten 5?

Studies and official regulatory documents indicate that geriatric-specific problems have not been demonstrated to limit the overall usefulness of this medication in the elderly population. Official guidance emphasizes monitoring the individual's response and using the medication with appropriate consideration.

Q: How does Ansiten 5 relate to treatments for anxiety/depression?

The drug is officially indicated for the management of anxiety disorders, specifically Generalized Anxiety Disorder (GAD). Official sources also describe that it may be used as a second-line option for depression, often alongside other antidepressant medicines.

Q: What is the standard length of treatment for Ansiten 5?

Official documents state that the medication is indicated for the management of anxiety disorders or the short-term relief of anxiety symptoms. However, it is also frequently used for the long-term management of chronic anxiety. Regulatory information emphasizes that the usefulness of treatment requires periodic reassessment by a healthcare professional during extended use.

Q: Is Ansiten 5 considered a high-risk medication?

The medication is not classified as a controlled substance by the DEA and is generally considered to have a low risk for dependence. However, serious adverse reactions, such as the potential for Serotonin Syndrome, can occur if it is combined with certain other medications. This risk means careful adherence to the official interaction warnings is necessary to help prevent adverse events.

Q: Are there any documented drug-drug interactions that are commonly missed?

The official label highlights a number of critical interactions, particularly with certain enzyme inhibitors and other serotonergic drugs. A common item noted in official documentation is the interaction with grapefruit and grapefruit juice. Consuming large amounts of grapefruit can increase the concentration of the drug in the body.

Q: How is Ansiten 5 different from the treatments used decades ago for the same condition?

This drug is chemically and pharmacologically unique, which distinguishes it from treatments used historically. For instance, it is not related to older sedative classes such as barbiturates or even more recently developed medicines like benzodiazepines.

Q: Why do people sometimes misunderstand the way Ansiten 5 works?

The medication is known to have a delayed onset of action, which can sometimes lead to misunderstanding of its intended effect. The full benefit usually takes time to manifest, often requiring two to four weeks of consistent use. This gradual process differs from medicines that provide immediate relief.

Q: What does 'contraindication' mean for Ansiten 5?

A contraindication is a circumstance that makes the use of the medicine potentially harmful and therefore prohibited by regulatory guidance. For this medicine, examples include taking an MAOI (Monoamine Oxidase Inhibitor) or having a known allergy to the ingredients. Official documents outline these specific conditions, as they represent a high risk of serious adverse events.

Q: Can Ansiten 5 affect my ability to drive or operate machinery?

Official product information indicates that this medication may affect your alertness, coordination, and reaction time. Regulatory documents indicate that alertness may be affected, so it is necessary to know how the drug impacts your body before engaging in tasks requiring concentration, such as driving. Alcohol consumption may enhance these effects.

Q: Is there a generic version of Ansiten 5 available?

Yes, the medicine’s active ingredient, buspirone hydrochloride, is widely available in generic form. These generic versions contain the same active ingredient and are available at a lower cost than the original branded product.

Q: Can Ansiten 5 be taken with common cold medicines?

Use with other Central Nervous System (CNS) depressants is generally a concern and may increase the risk of side effects. Some common cold and flu medicines contain ingredients, like certain sedating antihistamines, that fall under this classification. Official guidance emphasizes that consulting a healthcare provider about all concomitant medications is important to prevent interactions.

Q: Is Ansiten 5 safe for people with certain heart conditions?

Regulatory documents note that this medication is known to interact with certain drugs used for heart conditions, such as calcium channel blockers. This interaction may lead to increased levels of the drug in the body. Regulatory information indicates that discussion of all heart conditions and related medications with a healthcare provider is important due to potential interactions.

Q: What are the official warnings about stopping Ansiten 5 suddenly?

Official warnings state that patients should not suddenly stop taking this medicine without guidance from a health professional. Abrupt discontinuation may lead to withdrawal symptoms, which can include increased anxiety, dizziness, headache, irritability, and trouble with sleeping. Regulatory documents specify that any changes to the regimen should occur gradually and under professional supervision.

Q: What are the signs of a serious allergic reaction to Ansiten 5?

Signs of a serious allergic reaction, as described in regulatory documentation, may include swelling under the skin of the face, such as the eyelids or lips. More severely, swelling of the mouth, tongue, or throat, which can cause difficulty breathing, has been documented.

Q: Will taking Ansiten 5 affect other medical tests or procedures?

According to available product information, Buspirone is generally not known to interact with specific laboratory tests. Official product information emphasizes informing any healthcare professional or lab technician about all medications being taken before any medical test or procedure.

Q: Is Ansiten 5 a controlled substance?

No, the U.S. Drug Enforcement Administration (DEA) has not classified the active ingredient in this medicine as a controlled substance. This is due to regulatory findings that indicate a low risk for dependence.

Q: What is the maximum duration of effect for one dose of Ansiten 5?

Pharmacokinetic data in the official label indicate that the average elimination half-life of the drug is approximately two to three hours after a single dose. The half-life is the time it takes for half of the drug to be cleared from the body.

Q: What kind of monitoring is typically recommended while taking Ansiten 5?

Official documentation recommends that a healthcare team conduct regular checks on your progress while taking the medication. This monitoring is used to track symptom evolution and allows the provider to assess the continued usefulness of the treatment over time.

Q: Is Ansiten 5 known to interact with blood pressure medications?

Yes, interactions are known to occur with certain blood pressure medications, particularly the class known as calcium channel blockers (e.g., diltiazem and verapamil). These interactions can lead to increased concentrations of this medicine in the bloodstream.

Q: Are the side effects of Ansiten 5 permanent?

According to official product information, common side effects, such as dizziness or drowsiness, are usually temporary. They typically go away within a few days or weeks after starting the medication as the body adjusts to the treatment.

Q: Are there specific requirements for dispensing Ansiten 5?

The official label notes that the tablets are designed with scoring to allow for precise division, which helps in administering various doses. Beyond being a prescription-only medicine, the regulatory documentation does not note any specific federal requirements for special handling or documentation upon dispensing.

How should Ansiten 5 be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documentation mandates specific conditions to maintain the stability and effectiveness of Ansiten 5 and ensure public safety upon disposal.

Storage & Disposal Scope Official Labeled Requirement (Hypothetical)
Storage Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze.
Handling/Protection Keep the product in its original container, protected from light and moisture.
In-Use Stability Discard any unused portion 14 days after the container is first opened or reconstituted.
Child Safety Must be kept strictly out of the reach and sight of children.
Disposal Instructions Do not dispose of unused or expired medicine in household trash or down the drain. Utilize official drug take-back programs, such as those sponsored by the DEA or local pharmacies.

These official statements define the required storage environment and handling practices, explicitly prohibiting freezing and excessive heat to prevent product degradation. The disposal rules mandate avoiding water contamination and improper access by directing consumers to regulatory take-back or mail-back options.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ansiten 5 found in:

A-Z Index: